Shevorykin Alina, Carl Ellen, Mahoney Martin C, Hanlon Colleen A, Liskiewicz Amylynn, Rivard Cheryl, Alberico Ronald, Belal Ahmed, Bensch Lindsey, Vantucci Darian, Thorner Hannah, Marion Matthew, Bickel Warren K, Sheffer Christine E
Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Wake Forest School of Medicine, Winston-Salem, NC, United States.
Front Hum Neurosci. 2022 Jul 5;16:920383. doi: 10.3389/fnhum.2022.920383. eCollection 2022.
Repetitive transcranial magnetic stimulation (rTMS) is a novel treatment for smoking cessation and delay discounting rate is novel therapeutic target. Research to determine optimal therapeutic targets and dosing parameters for long-term smoking cessation is needed. Due to potential biases and confounds introduced by the COVID-19 pandemic, we report preliminary results from an ongoing study among participants who reached study end prior to the pandemic.
In a 3 × 2 randomized factorial design, participants ( = 23) received 900 pulses of 20 Hz rTMS to the left dorsolateral prefrontal cortex (PFC) in one of three Durations (8, 12, or 16 days of stimulation) and two Intensities (1 or 2 sessions per day). We examined direction and magnitude of the effect sizes on latency to relapse, 6-month point-prevalence abstinence rates, research burden, and delay discounting rates.
A large effect size was found for Duration and a medium for Intensity for latency to relapse. Increasing Duration increased the odds of abstinence 7-8-fold while increasing Intensity doubled the odds of abstinence. A large effect size was found for Duration, a small for Intensity for delay discounting rate. Increasing Duration and Intensity had a small effect on participant burden.
Findings provide preliminary support for delay discounting as a therapeutic target and for increasing Duration and Intensity to achieve larger effect sizes for long-term smoking cessation and will provide a pre-pandemic comparison for data collected during the pandemic.
[www.ClinicalTrials.gov], identifier [NCT03865472].
重复经颅磁刺激（rTMS）是一种用于戒烟的新型治疗方法，而延迟折扣率是一个新的治疗靶点。需要开展研究以确定长期戒烟的最佳治疗靶点和给药参数。由于2019年冠状病毒病（COVID-19）大流行引入了潜在的偏差和混杂因素，我们报告了一项正在进行的研究的初步结果，该研究的参与者在大流行之前就达到了研究终点。
采用3×2随机析因设计，参与者（n = 23）在三个持续时间（8、12或16天的刺激）和两种强度（每天1或2次治疗）之一中，接受对左侧背外侧前额叶皮质（PFC）进行900次脉冲的20Hz rTMS治疗。我们研究了效应大小对复发潜伏期、6个月点患病率戒烟率、研究负担和延迟折扣率的影响方向和大小。
发现持续时间对复发潜伏期的效应大小较大，强度的效应大小为中等。持续时间增加使戒烟几率增加7 - 8倍，而强度增加使戒烟几率翻倍。发现持续时间对延迟折扣率的效应大小较大，强度的效应大小较小。持续时间和强度的增加对参与者负担的影响较小。
研究结果为将延迟折扣作为治疗靶点以及增加持续时间和强度以实现长期戒烟的更大效应大小提供了初步支持，并将为大流行期间收集的数据提供大流行前的比较。
[www.ClinicalTrials.gov]，标识符 [NCT03865472]。
